For the quarter ending 2026-03-31, SNDX made $64,864K in revenue. -$42,673K in net income. Net profit margin of -65.79%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 64,864 | 88,523 | 45,871 | 37,958 |
| Cost of product sales | 2,633 | 1,902* | 2,100 | 1,279 |
| Research and development | 58,845 | 186,328* | 56,280 | 62,227 |
| Selling, general and administrative | 37,588 | 46,599* | 44,917 | 43,805 |
| Collaboration loss | 0 | - | - | - |
| Total operating expenses | 99,066 | 234,828 | 103,297 | 107,311 |
| Loss from operations | -34,202 | -146,305 | -57,426 | -69,353 |
| Royalty interest expense | 11,846 | 11,999* | 8,283 | 7,854 |
| Other expense | - | - | - | 586 |
| Other interest expense | 0 | 0* | 0 | 4 |
| Interest income | 3,561 | 5,902* | 5,269 | 5,950 |
| Other expense | -186 | -458* | -275 | - |
| Total other (expense) income, net | -8,471 | -6,555 | -3,289 | -2,494 |
| Net loss | -42,673 | -152,860 | -60,715 | -71,847 |
| Basic EPS | -0.48 | -1.75 | -0.7 | -0.83 |
| Diluted EPS | -0.48 | -1.75 | -0.7 | -0.83 |
| Basic Average Shares | 88,255,636 | 87,372,322 | 86,620,992 | 86,337,237 |
| Diluted Average Shares | 88,255,636 | 87,372,322 | 86,620,992 | 86,337,237 |
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)